AbbVie ABBV shares are moving higher in Monday’s pre-market session after the company raised guidance.
Full year guidance is now expected between $3.06 and $3.16 versus $3.00 to $3.10 announced at the end of January. This is a two percent increase from the midpoint. The company also announced that the guidance does not include any potential earnings from the U.S. launch of its hepatitis C therapy that is under accelerated review by the FDA.
Shares of AbbVie were last trading at $54.49, up 2.23 percent since Friday’s close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.